GGTLC1 and metabolic dysfunction-associated steatotic liver disease: Clinical studies have shown that exogenous melatonin lowers hepatic aminotransferases and gamma-glutamyl transpeptidase and lipid profile indicators, and it is assumed that melatonin should be practically important in the prevention of the progression of liver damage in NAFLD and NASH.